These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 11183022)

  • 1. The management of depression: the implications for managed care--roundtable discussion: Part 3.
    Vodoor M; Southwell YP; Grubin M; Wert S; Kang-Cipolla L; Denes A; Evans S; Mason J; Zarr M; Osborn L; Kenney J; Hunkeler E; Waugh W; Bull S
    Manag Care Interface; 2000; Suppl B():26-32. PubMed ID: 11183022
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The management of depression: the implications for managed care--roundtable discussion: Part 2.
    Arikian S; Casciano J; Kang-Cipolla L; Vodoor M; Grubin M; Clark D; Waugh W; Kelsey J; Osborn LW
    Manag Care Interface; 2000; Suppl B():19-25, 32. PubMed ID: 11183021
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Depression in the workplace: negative effects, perspective on drug costs and benefit solutions.
    Riotto M
    Benefits Q; 2001; 17(2):37-48. PubMed ID: 11372474
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The management of depression: the implications for managed care--roundtable discussion: Part 1.
    Kelsey J; Vodoor M; Hunkeler E; Zarr M; Mason J
    Manag Care Interface; 2000; Suppl B():12-8. PubMed ID: 11183020
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparisons of clinical efficacy.
    Ferrier IN
    Br J Psychiatry Suppl; 1993 Jul; (20):25-8. PubMed ID: 8352913
    [No Abstract]   [Full Text] [Related]  

  • 6. Newer antidepressants for the treatment of depression in adults.
    Hatcher S; Arroll B
    BMJ; 2012 Jan; 344():d8300. PubMed ID: 22262785
    [No Abstract]   [Full Text] [Related]  

  • 7. Antidepressant adherence and medical resource use among managed care patients with anxiety disorders.
    Stein MB; Cantrell CR; Sokol MC; Eaddy MT; Shah MB
    Psychiatr Serv; 2006 May; 57(5):673-80. PubMed ID: 16675762
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effective treatment of depression with selective serotonin reuptake inhibitors.
    Panzarino PJ; Nash DB
    Am J Manag Care; 2001 Feb; 7(2):173-84. PubMed ID: 11216334
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of major depressive disorder in children and adolescents.
    Ramchandani P
    BMJ; 2004 Jan; 328(7430):3-4. PubMed ID: 14703522
    [No Abstract]   [Full Text] [Related]  

  • 10. Medical resource use and cost of venlafaxine or tricyclic antidepressant therapy. Following selective serotonin reuptake inhibitor therapy for depression.
    Griffiths RI; Sullivan EM; Frank RG; Strauss MJ; Herbert RJ; Clouse J; Goldman HH
    Pharmacoeconomics; 1999 May; 15(5):495-505. PubMed ID: 10537966
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Economic evaluation of antidepressive agents: a systematic critique of experimental and observational studies.
    Barbui C; Percudani M; Hotopf M
    J Clin Psychopharmacol; 2003 Apr; 23(2):145-54. PubMed ID: 12640216
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of antidepressant treatments on health service utilization and medical costs among patients with depression: a nationwide population-based retrospective cohort study in Taiwan.
    Su KP; Tang CH; Chang HC; Chiu WC; Lu N; Huang KC
    Int Clin Psychopharmacol; 2019 Jul; 34(4):170-178. PubMed ID: 30964763
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improving psychiatric drug benefit management: II. Kaiser Permanente's approach to SSRIs.
    Sabin JE; Daniels N
    Psychiatr Serv; 2003 Oct; 54(10):1343-4,1349. PubMed ID: 14557518
    [No Abstract]   [Full Text] [Related]  

  • 14. Retrospective analysis of the health-care costs of bupropion sustained release in comparison with other antidepressants.
    Poret AW; Neslusan C; Ricci JF; Wang S; Khan ZM; Kwong JW
    Value Health; 2001; 4(5):362-9. PubMed ID: 11705126
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Implications of an SSRI generic step therapy pharmacy benefit design: an economic model in anxiety disorders.
    Panzer PE; Regan TS; Chiao E; Sarnes MW
    Am J Manag Care; 2005 Oct; 11(12 Suppl):S370-9. PubMed ID: 16236019
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacy and medical costs associated with switching between venlafaxine and SSRI antidepressant therapy for the treatment of major depressive disorder.
    Khandker RK; Kruzikas DT; McLaughlin TP
    J Manag Care Pharm; 2008 Jun; 14(5):426-41. PubMed ID: 18597572
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-benefit & cost-effectiveness analysis of the rapid onset of selective serotonin reuptake inhibitors by augmentation.
    Tome MB; Isaac MT
    Int J Psychiatry Med; 1997; 27(4):377-90. PubMed ID: 9565733
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Depression treatment.
    Goldstein AO; Ives TJ
    J Fam Pract; 1994 Aug; 39(2):114, 116. PubMed ID: 8057059
    [No Abstract]   [Full Text] [Related]  

  • 19. Course and cost of treatment for depression with fluoxetine, paroxetine, and sertraline.
    Russell JM; Berndt ER; Miceli R; Colucci S; Grudzinski AN
    Am J Manag Care; 1999 May; 5(5):597-606. PubMed ID: 10537866
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Depression: the benefits of early and appropriate treatment.
    Halfin A
    Am J Manag Care; 2007 Nov; 13(4 Suppl):S92-7. PubMed ID: 18041868
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.